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Abstract 
 
Aim: The small European Mediterranean island state of Malta is a highly prevalent type 2 diabetes 
(T2DM) country. Over recent decades drastic environmental, cultural and ethnic changes occurred 
and it was considered timely to undergo a cross-sectional survey to establish up-to-date prevalence 
of T2DM, its socio-geographical distribution and ultimately estimating the economic burden of 
T2DM.  
Methods: A health examination survey was conducted (2014-16) including a representative 
sample of the adult population stratified by 18-70 years, gender and locality (n=3,947; males 
n=1,997 male). The survey consisted of a socio-demographic questionnaire, various health 
examination measurements and blood samples for fasting blood glucose (FBG). Prevalence for 
T2DM (depending on medical history, medication and FBG >7mmol/L) were calculated for the 
general population as well as for each of the districts making up the Maltese Islands. The economic 
burden of T2DM for 2017 and projected burden for 2045 were calculated using secondary sources 
and by incorporating 2% compound interest per annum respectively.  
Results: A total response rate of 47.15% was obtained, with a mean age of 48 years for males and 
46 years for females. Out of the total adjusted population (n=3,947, male n=1,998), the prevalence 
of T2DM was of 10.31%, with 6.31% already known to have T2DM while 4% were newly 
diagnosed. Females were diagnosed with T2DM at an earlier age than the males. No significant 
geographical T2DM prevalence differences were established. The total annual diabetes health care 
expenditure was approximately €107,316,517.82 for 2017, while the projected expenditure for 
2045 was estimated at €244,136,040.  
Conclusion: Malta is a country with a high prevalence of diabetes. The females were observed to 
be at an earlier risk of developing undiagnosed diabetes compared to males. Although geographical 
location did not appear to have significant effect on T2DM distribution, this disease contributes to 
a high economic burden. The expected exponential increase in diabetes prevalence is subsequently 
expected to affect negatively the healthcare expenditure. This puts forward the recommendation 
for development of early screening programmes as part of preventive action strategies.  
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Introduction 
Type 2 diabetes mellitus (T2DM) is a global epidemic 
with an estimated 463 million adults (20-79 years) 
suffering from this condition in 2019 (1). The 
Mediterranean island of Malta is no exception. In 
Malta, diabetes has been reported to be a health 
problem since the eighteenth century (2). The first 
epidemiological study aiming at assessing the 
prevalence of T2DM in Malta was conducted in 1964 
(3). In 1981, the World Health Organization (WHO) 
conducted the first national representative diabetes 
prevalence study in Malta (4). More recently, a pilot 
study was conducted in 2010 - the European Health 
Examination Survey (EHES) (5). This gave an 
estimate of the diabetes burden in Malta (5). Different 
studies reported increasingly higher diabetes 
prevalence within the Maltese population, often higher 
than neighbouring countries (1). Consequently, Malta 
was considered a Mediterranean hub for diabetes (6). 
Over recent years, Malta has sustained a cultural 
change, with more ethnical and socio-economic 
diversity, and new variety in the genetic imprints, as 
well as a shift to a more Westernised lifestyle (7). All 
these factors are contributors for population metabolic 
transition, which could possibly increase the diabetes 
prevalence within the Maltese population (7).  
A national representative survey was undertaken 
between 2014 and 2016 to update the dysglycaemic 
status of Malta (8). It was hypothesised that with the 
drastic environmental, cultural and ethnic changes that 
have occurred in Malta over the past few decades, the 
prevalence of T2DM and its distribution among the 
population have altered from the previous studies. The 
aim of this study was to update the prevalence of 
T2DM in Malta as well as to determine the socio-
geographical distribution of the disease and ultimately 
estimate the economic burden 
 
Methods 
The University of Malta conducted a nationally 
representative health examination survey (2014 – 
2016) entitled SAHHTEK (your health). The detailed 
study methodology can be found elsewhere (8). 
Briefly, a population-based sample stratified by age 
(18-70 years), gender and locality (approximately 1% 
from each of the 68 towns) was obtained from a 
national register. The selected individuals (n=3,947; 
males n=1,998) with a mean age of 48 years for males 
and 46 years for females, were invited to participate in 
the survey that consisted of a previously validated 
questionnaire, blood pressure measurements, weight, 
height, waist circumference and hip circumference 
measurements. Blood samples  
 
for fasting blood glucose and a lipid profile were also 
gathered. Informed written consent was obtained from 
every participant. Ethical and data protection 
approvals were granted from the University of Malta 
Research Ethical Committee (UREC) and the 
Information and the Data Protection national 
commissioner, respectively.  
Participants obtaining a fasting blood glucose (FBG) 
level between 5.60 to 6.99 mmol/L were referred to as 
Impaired Fasting Glucose (IFG), while those with a 
FBG >=7 mmol/L were considered as newly 
diagnosed diabetes mellitus, provided they were not 
previously diagnosed as diabetics or were on oral 
hypoglycaemic agents (9). Participants with a previous 
history of diabetes mellitus or on oral hypoglycemic 
agents, irrespective of their measured fasting plasma 
glucose, were considered as cases of previously 
diagnosed diabetes mellitus. 
The global T2DM prevalence level was calculated by 
dividing the sum of newly diagnosed and previously 
diagnosed diabetics over the total number of 
participating individuals. The prevalence levels for 
previously diagnosed diabetes and newly diagnosed 
diabetes were established separately and in total. The 
prevalence levels were stratified by age and gender 
and compared to the previously reported prevalence 
levels by the WHO 1981 study (4).  
Following the Eurostat system of Local 
Administrative Units (LAUs), the diabetes prevalence 
was stratified into the six districts of Southern harbour, 
Northern harbour, South Eastern, Western, Northern 
and Gozo districts (10). For each district, the T2DM 
prevalence level (global, previously and newly 
diagnosed T2DM) were calculated.  
The economic burden of T2DM was calculated by 
multiplying the total diabetic Maltese population by 
the estimated mean diabetes-related expenditure per 
person for Malta as reported by the International 
Diabetes Federation (IDF) Atlas in 2017 (11). This 
expenditure incorporated the provision of health 
services (preventive and curative), family planning 
activities, nutritional activities, emergency aid for both 
public and private healthcare expenditures (11). The 
original IDF estimation for healthcare expenditure was 
based on the IDF diabetes prevalence (an over-
estimation for Malta), the United Nations population 
estimates, the WHO annual health care expenditure 
and mortality rates, as well as ratios of healthcare 
expenditure for diabetics compared to non-diabetics 
(11-14).  
The progressive diabetes prevalence between the two-
health examination surveys (1981 and 2016) was 
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calculated, while assuming that the progressive 
prevalence level remained constant across the 35 years 
duration. This progressive prevalence level was 
utilized to project the diabetes prevalence for the year 
2045. The previously calculated diabetes expenditure 
per person was also projected for the year 2045 by 
incorporating a 2% compound interest increase per 
annum (15). Using the EUROSTAT projected total 
Maltese population for the year 2045, the projected 
diabetes prevalence level for 2045 was then estimated 
(16). This 2045 diabetes population estimate was used 
to estimate the diabetes economic burden.  
 
Results 
A total of 3,947 adults (1,998 male and 1,949 female) 
were invited to participate in the health examination 
survey held between November 2014 and November 
2015. Of these, 1,861 adults (836 male and 1,025 
female) participated, giving a response rate of 47.15% 
(p=<0.01). Since the responders were found to be 
significantly different from the non-responders, a 
weighting factor was applied to each of the responder. 
The weighting factor enabled the data to maintain its 
representative nature by ensuring that each town was 
represented by 1% by each age and sex. A detailed 
description of the weighting protocol can be found 
elsewhere (8). The final weighted (adjusted) 
population was of 3,947 (males n=1998), of whom 
10.31% (CI 95%: 9.40%-11.30%) suffered from 
diabetes mellitus. This included those previously 
diagnosed (6.31%, CI 95%: 5.59%-7.11%), as well as 
newly diagnosed (4.00% CI 95%: 3.43%-4.66%) 
diabetics. Comparing this study’s results to the last 
nationally representative study (1981), an increase in 
diabetes prevalence rate was observed (Figure 1). A 
steeper increase was observed between 1981 and 2016 
amongst the newly diagnosed diabetics. A slight 
increase was also observed when the current study was 
compared to the European health examination pilot 
study (n=212) conducted in 2010 (total diabetes 
prevalence of 9.8%).  
On age and gender stratification of the diabetes 
prevalence, the female population exhibited an earlier 
onset of diabetes mellitus (30-39 years) when 
compared to the male population (40-49 years) 
amongst the current study population. Figure 2 
compares the global diabetes prevalence levels 
between the 1981 and 2016 studies, by age group and 
gender. A more evident difference in the diabetes 
prevalence levels could be observed between the two 
studies amongst the elderly population (70 years). 
 
 
 
Figure 1. Comparison between the diabetes prevalence rate amongst the WHO 1981 and SAHHTEK 2014 – 
2016 studies 
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Figure 2. Diabetes prevalence rates amongst the WHO 1981 and SAHHTEK 2014 – 2016 studies, by age 
groups and gender 
 
 
 
 
 
The diabetes prevalence differed across the six 
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prevalence rates (Figure 3). The Southern harbour, 
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newly diagnosed diabetes prevalence level of 5%. 
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diagnosed diabetes prevalence level as compared to 
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Figure 3. Global diabetes prevalence levels by district in Malta 2014 – 2016 
 
 
 
 
 
 
The Maltese diabetes economic burden for 2017 was 
estimated to be €2,416 per diabetic individual per year 
(11). Considering the global diabetes prevalence of 
10.31% and the total Maltese adult population for 
2017 to be 430,835 people, the total annual diabetes 
health care expenditure was estimated to be 
approximately €107,316,517.82 (€97,844,351.84 – 
€117,621,401.68). The projected mean diabetes 
expenditure per individual for the year 2045 is 
expected to be €4,206. While, the projected global 
diabetes prevalence for the year 2045 is expected to be 
12.47% and the total projected Maltese population 
(2045) to be 465,440 adults. Hence, the total diabetes 
healthcare expenditure for that year would be 
approximately €244,136,040.  
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Figure 4. Previously diagnosed and newly diagnosed prevalence rates  
by district 
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Discussion 
Diabetes mellitus type 2 is a major health and 
economic burden at individual, population and global 
levels (1,15). Over 35 years (1981 to 2016), an 
exponential rise was observed in the diabetes 
prevalence rate of Malta, which is consistent with the 
ongoing global epidemic (1). The majority of this rise 
is attributed to population growth and ageing (17). 
Consequently, the economic burden of diabetes will 
continue to increase in the years to come, particularly 
among the ever-aging population. Concomitantly, the 
global economic burden for this disease is expected to 
increase by 104 billion from 2017 to 2045 (11). A 
parallel transition is envisaged for the Maltese islands, 
with a projected estimated increase of €136,819,523 in 
the economic annual burden of the disease from 2017 
to 2045. Even though the current and projected official 
IDF health expenditure figures are inflated, the 
growing economic burden of diabetes on the health 
system is significant and calls for action.  
The geographical residing location of the Maltese 
population may have an effect on the diabetes burden. 
The highest undiagnosed diabetes levels were 
observed within the Northern harbour, Southern 
harbour and Gozo districts, even though not 
statistically different from the other districts, may 
underlie some important trends. Further research is 
recommended with possibility of targeted preventive 
actions. It is well documented that undiagnosed 
diabetes is subject to higher healthcare usage and 
therefore incur a larger healthcare expenditure (1). 
The presence of diabetes mellitus was observed to 
become frequent from a relatively young age, 
especially for the female population in Malta. 
Considering that 1 in 10 adults in Malta eventually 
suffer from diabetes, it is worth considering the 
established criteria for early screening of this 
condition in the population, given its frequency and 
impact. In spite of the fact that international guidelines 
suggest that routine diabetes check-ups should initiate 
from the age of 45 years, it is evident that for Malta 
this should be even earlier and possibly from the age 
of 30 years (9).  
Over 35 years, there has also been a shift in the gender 
predominance of type 2 diabetes mellitus. The current 
study demonstrates a male diabetes predominance 
contrasting with findings of the 1981 and 2010 
surveys, which showed a female diabetic 
predominance. Similarly, a female predominance was 
also reported by a Norwegian health examination 
survey conducted between 1984 and 1986 with a 
gender shift on repeating the survey between 1995 and 
1997 (18). This gender shift is in keeping with the rest  
 
of the world, where diabetes seemingly now affects 
more males than females (11). The male diabetes 
predominance has been reported to be due to an 
increasing obesity level, from a young age, when 
compared to the female population. This increase in 
obesity susceptibility could have been the result of a 
change in social factors (18). Nowadays, the majority 
of the jobs are sedentary in contrast to the early part of 
the past century where jobs were more labour 
intensive, and travelling was done by foot or bicycle 
(18). Furthermore, males have greater hepatic and 
visceral fat stores and are physiologically less insulin 
sensitive than females (19). Therefore, one can 
hypothesize that males require less weight gain than 
females to develop T2DM, which would explain the 
male diabetes predominance. In fact, it was reported 
that biological differences between males and females 
are the fundamental components for the development 
of T2DM (20,21). However, environmental, 
socioeconomic and cultural factors also play a role in 
T2DM susceptibility and gender differences (20-22). 
These may be the underlying factors contributing to 
the high diabetes prevalence rate. It is a very intriguing 
fact that Malta “excels” in diabetes and obesity rates 
when compared to neighbouring countries. Malta is 
highly dependent on imports of foods and goods 
especially from Sicily, which is another Island in the 
Mediterranean Sea, but yet, not as diabetic prevalent 
as Malta. This raises the question whether it is the 
small size of the island along with the islandness state 
that are contributing to such a health burden or is it the 
multi-cultural and environmental changes that took 
place in Malta. This calls for further research and 
interventions.  
 
Study limitations 
The response rate obtained was 47.15%. This was 
considered as an adequate response rate considering 
the invasive measurements performed. In fact, when 
compared to other European Health Examination 
surveys such as the Czech edition of the European 
Health Examination Survey (EHES) obtained a 
response of 31.69% (23). While the better-established 
SHeS in Scotland managed a response rate of 64% 
from all across Scotland (24). However, potential 
selection bias might still have occurred. Responders 
may have been different to non-responders and it 
remains difficult to remove this bias altogether. The 
decision to conduct weighting of the data by age, 
gender and towns was an effort to try to maintain the 
representation characteristics. Even though the 
population data was weighted, some subgroups still 
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remained with small numbers. This may have affected 
the power of specific subgroups statistical testing, 
resulting in possible type II errors. Considering that 
the data collection took place over a period of one-
year, seasonal variations may have had an effect on the 
response rate as well as on the biological measures, 
such as blood pressure, FBG, blood lipid levels, BMI 
and waist circumference. The study was a health 
examination survey and hence clinical diagnosis could 
not be established. However, being a health 
examination survey high-risk population for particular 
conditions could be identified. The study does not 
cover the whole population but only a subset of the 
adult population. General demographic data was based 
on the published reports from 2013. The mean diabetes 
expenditure per individual was based on the IDF’s 
Maltese specific cost, which was generated from 
multiple sources. However, this expenditure did not 
differentiate between newly diagnosed and previously 
diagnosed diabetes, as well as it was based on over-
estimation of diabetes prevalence rate. The cost did not 
take in consideration intangible costs, which is 
difficult to quantify. The projections for 2045 were 
based on current conditions with the assumption that 
all demographic and risk factors would continue at 
their current rates. 
 
Conclusion 
Type 2 diabetes is an epidemic in Malta same as 
globally. The onset of newly diagnosed diabetes 
appears to affect females from the very young as the 
fourth decade of life irrespective of their geographical 
habitat. Furthermore, as the years progress, so do the 
estimated health expenditure contributed to this 
disease. This puts forward the recommendation that 
urgent preventive action is merited to tackle diabetes 
at a population level targeting the young generation. 
Such action would consequently reduce the health 
burden on the health care system and economy.  
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